Antibiotic-modified anticancer drug compound for gene non-toxic anticancer therapy and an anticancer pharmaceutical composition comprising the same

Antibiotic-modified anticancer drug that targets only mitochondria and acts without genetic alteration

This technology relates to an antibiotic-modified anticancer drug compound for gene non-toxic anticancer therapy and an anticancer pharmaceutical composition comprising the same.

Conventional chemotherapy damages nuclear DNA to kill cancer cells, leading to problems such as genetic alteration, cancer recurrence, and drug resistance.

The modified anticancer drug of this technology selectively targets only the mitochondria of cancer cells to exert therapeutic effects without causing genetic alteration, thereby preventing recurrence and effectively treating malignant tumors that are difficult to treat due to drug resistance.

‍

‍

Key Features:

• Antibiotic-modified anticancer drug compound that selectively targets mitochondria
• Gene non-toxic anticancer mechanism that acts without nuclear DNA damage
• Prevention of cancer recurrence through inhibition of genetic alteration
• Effective treatment for drug-resistant malignant tumors